CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

The Lancet
Original article

[Articles] Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial

Phase 3garetosmabGaretosmab

Read the original article

Published by The Lancet on September 28, 2026 10:30 PM

Read Original